RHYTHM PHARMACEUTICALS, INC. (RYTM)
About RHYTHM PHARMACEUTICALS, INC.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $189.8M
- Net income
- -$196.5M
- Total assets
- $480.2M
- Market cap
- $5.9B
- Gross margin
- 89.7%
- Operating margin
- -101.2%
- Net margin
- -103.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $189.8M
- Cost of revenue
- $19.5M
- Gross profit
- $170.3M
- Operating expenses
- $362.3M
- Operating income
- -$192.0M
- Income tax
- $497.0K
- Net income
- -$196.5M
- EPS (basic)
- $-3.11
- EPS (diluted)
- $-3.11
Balance sheet
- Total assets
- $480.2M
- Current assets
- $466.9M
- Total liabilities
- $210.2M
- Current liabilities
- $105.9M
- Shareholders’ equity
- $139.1M
Cash flow
- Operating cash flow
- -$115.7M
- Investing cash flow
- -$137.2M
- Financing cash flow
- $218.0M
- Net cash flow
- -$34.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $5.9B
- EPS (diluted)
- $-3.11
- Shares outstanding
- 58.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 5, 2017
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price
- Reported a net loss of $196.5M in FY2025.
- Revenue grew 5916% from FY2021 to FY2025.
- Gross margin of 89.7%, net margin -103.6%.
- Trading 13% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review RHYTHM PHARMACEUTICALS, INC..
Write a review
News about RHYTHM PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
Rhythm Pharmaceuticals, Inc.: frequently asked questions
Is Rhythm Pharmaceuticals, Inc. an American company?
Rhythm Pharmaceuticals, Inc. is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Rhythm Pharmaceuticals, Inc. headquartered?
Rhythm Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts, United States.
Is Rhythm Pharmaceuticals, Inc. publicly traded?
Yes — Rhythm Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol RYTM on the NASDAQ.
What does Rhythm Pharmaceuticals, Inc. do?
Rhythm Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Rhythm Pharmaceuticals, Inc. founded?
Rhythm Pharmaceuticals, Inc. was founded in 2008.
